Literature DB >> 8660070

Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.

K Wheeler1, J M Chessells, C C Bailey, S M Richards.   

Abstract

The benefits of achieving a long term event free survival of 60-70% by using increasingly intense treatment regimens must be weighed against the increased risk of treatment toxicity. From 1985 to 1990, 1612 children with childhood acute lymphoblastic leukaemia (ALL) in the UK were treated on MRC UKALL X with intensive induction therapy, central nervous system directed therapy (cranial irradiation and intrathecal methotrexate), and continuing treatment for two years. There was a randomisation to receive blocks of additional intensification treatment at five weeks, 20 weeks, not at all, or both. The five year disease free survival was 71% for children randomised to two blocks of intensification, a 14% improvement on children randomised to no intensification treatment. Treatment related mortality in this national multicentre study has been analysed for induction and first remission (including those after intensification treatment). There were 38 induction deaths, 2.3% and 53 deaths in first remission, 3.3% (including those from a second malignancy). Thirty one (84%) of the induction deaths followed an infection: bacterial in 22 and fungal in nine. Thirty seven infective remission deaths occurred: bacterial in 11, viral in 16, fungal in seven, and three caused by Pneumocystis carinii pneumonia. Ten of these deaths followed a block of intensification treatment. The majority of noninfective remission deaths followed the development of a second tumour. Risk analysis for an induction death showed girls and children with Down's syndrome to be at greater risk. For deaths in first remission analysis showed an increased risk for bone marrow transplant (BMT) patients and children with Down's syndrome. There was no effect of age and leucocyte count for either group. Most significantly when BMT patients were excluded from the analysis, intensification treatment did not increase the risk of remission death.

Entities:  

Mesh:

Year:  1996        PMID: 8660070      PMCID: PMC1511507          DOI: 10.1136/adc.74.2.101

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  19 in total

1.  Abnormal serum IgG subclass pattern in children with Down's syndrome.

Authors:  G Annerén; C G Magnusson; G Lilja; S L Nordvall
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

2.  Necrotising fasciitis in leukaemic children.

Authors:  J Lou; C H Low
Journal:  Ann Acad Med Singapore       Date:  1990-03       Impact factor: 2.473

3.  Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood).

Authors:  O B Eden; J S Lilleyman; S Richards; M P Shaw; J Peto
Journal:  Br J Haematol       Date:  1991-06       Impact factor: 6.998

4.  Prognosis of Down's syndrome with acute leukaemia.

Authors:  G A Levitt; C A Stiller; J M Chessells
Journal:  Arch Dis Child       Date:  1990-02       Impact factor: 3.791

5.  Second neoplasms after acute lymphoblastic leukemia in childhood.

Authors:  J P Neglia; A T Meadows; L L Robison; T H Kim; W A Newton; F B Ruymann; H N Sather; G D Hammond
Journal:  N Engl J Med       Date:  1991-11-07       Impact factor: 91.245

6.  Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study).

Authors:  C R Pinkerton; A Bowman; H Holtzel; J M Chessells
Journal:  Arch Dis Child       Date:  1987-01       Impact factor: 3.791

Review 7.  Infections in the compromised child.

Authors:  C Viscoli; E Castagnola; D Rogers
Journal:  Baillieres Clin Haematol       Date:  1991-04

8.  Causes of mortality in children with acute lymphocytic leukemia.

Authors:  V P Choudhry; L Krishnamurthy; L S Arya; N Desai; H Pati
Journal:  Indian Pediatr       Date:  1992-06       Impact factor: 1.411

9.  Incidence of second primary tumours among childhood cancer survivors.

Authors:  M M Hawkins; G J Draper; J E Kingston
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  10 in total

Review 1.  Therapeutic trials in childhood ALL: what's their future?

Authors:  O B Eden
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

Review 2.  Recent advances in management of acute leukaemia.

Authors:  J M Chessells
Journal:  Arch Dis Child       Date:  2000-06       Impact factor: 3.791

3.  Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994.

Authors:  C A Stiller; E M Eatock
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

4.  Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

Authors:  Kathleen A Meeske; Lingyun Ji; David R Freyer; Paul Gaynon; Kathleen Ruccione; Anna Butturini; Vassilios I Avramis; Stuart Siegel; Yousif Matloub; Nita L Seibel; Richard Sposto
Journal:  Pediatr Blood Cancer       Date:  2015-07-14       Impact factor: 3.167

5.  Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.

Authors:  J M Chessells; G Harrison; S M Richards; C C Bailey; F G Hill; B E Gibson; I M Hann
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

6.  Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis.

Authors:  Emily R Finch; Laura J Janke; Colton A Smith; Seth E Karol; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Ching-Hon Pui; Joshua Wolf; Mary V Relling
Journal:  Pediatr Blood Cancer       Date:  2019-02-13       Impact factor: 3.167

7.  Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.

Authors:  J R Roberson; H L Spraker; J Shelso; Y Zhou; H Inaba; M L Metzger; J E Rubnitz; R C Ribeiro; J T Sandlund; S Jeha; C-H Pui; S C Howard
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

Review 8.  Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.

Authors:  Niki Rensen; Reinoud Jbj Gemke; Elvira C van Dalen; Joost Rotteveel; Gertjan Jl Kaspers
Journal:  Cochrane Database Syst Rev       Date:  2017-11-06

9.  Induction-related mortality in adolescents and young adults with acute lymphoblastic leukemia in a resource-limited setting: do treatment-related complications create more impact than disease biology?

Authors:  Sergio I Inclan-Alarcon; Santiago Riviello-Goya; Kevin Teran-De-la-Sancha; Oscar M Fierro-Angulo; Aldo A Acosta-Medina; Roberta Demichelis-Gomez; Christianne Bourlon
Journal:  Blood Res       Date:  2022-03-31

10.  Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador.

Authors:  S Gupta; M Bonilla; S L Fuentes; M Caniza; S C Howard; R Barr; M L Greenberg; R Ribeiro; L Sung
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.